X4 Pharmaceuticals (NASDAQ:XFOR) Shares Break Below 50 Day Moving Average - Here's Why

Key Points

• X4 Pharmaceuticals fell below its 50-day moving average, trading as low as $3.14 and last at $3.17, down 5.4% in the session.
• Analyst sentiment is mixed but leans positive: four analysts rate the stock Buy, one Hold and one Sell, giving it a “Moderate Buy” consensus and an average $11.25 price target.
• The company beat quarterly estimates, reporting a loss of $0.13 per share versus expectations of $0.18 and revenue of $8.81 million versus $2.42 million expected. Insiders have sold 83,779 shares worth about $353,000 over the past 90 days.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report)'s stock price passed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $3.30 and traded as low as $3.14. X4 Pharmaceuticals shares last traded at $3.17, with a volume of 630,984 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently commented on XFOR shares. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an "overweight" rating and a $11.00 price target on the stock. Weiss Ratings cut shares of X4 Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, October 20th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $11.25.

X4 Pharmaceuticals Trading Down 5.4%

The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $314.31 million, a P/E ratio of -2.64 and a beta of 0.47. The firm has a 50 day moving average of $3.30 and a 200-day moving average of $3.79.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. The business had revenue of $8.81 million during the quarter, compared to the consensus estimate of $2.42 million. On average, equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO David Kirske sold 11,767 shares of the company's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the completion of the transaction, the chief financial officer owned 155,983 shares of the company's stock, valued at $446,111.38. This represents a 7.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Adam Craig sold 47,436 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the transaction, the chairman owned 328,651 shares of the company's stock, valued at $1,459,210.44. This represents a 12.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 83,779 shares of company stock worth $353,387 in the last 90 days. Insiders own 1.13% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. SummitTX Capital L.P. acquired a new stake in X4 Pharmaceuticals during the 1st quarter worth approximately $46,000. Pettinga Financial Advisors LLC acquired a new position in X4 Pharmaceuticals in the 2nd quarter valued at approximately $47,000. WINTON GROUP Ltd increased its position in X4 Pharmaceuticals by 35.8% in the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company's stock valued at $67,000 after acquiring an additional 3,800 shares during the period. AXQ Capital LP bought a new position in shares of X4 Pharmaceuticals during the second quarter valued at $107,000. Finally, Wellington Management Group LLP bought a new position in shares of X4 Pharmaceuticals during the second quarter valued at $242,000. Institutional investors own 72.03% of the company's stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company's research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4's lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.